$31bn required to speed up Covid-19 medicines for all: WHO
“It’s clear that to bring Covid-19 under control, and to save lives, we need effective vaccines, diagnostics and therapeutics – in unprecedented quantities and at unprecedented speed"
More than $31 billion is needed over the next 12 months to develop medicines that will be effective against Covid-19, and make them available to all people, the World Health Organization (WHO) and partners said on Friday.
They updated journalists on a recently announced initiative to speed up production of these treatments ahead of a major pledging summit known as the Access to Covid-19 Tools (ACT) Accelerator.
"It's clear that to bring Covid-19 under control, and to save lives, we need effective vaccines, diagnostics and therapeutics – in unprecedented quantities and at unprecedented speed," said Tedros Adhanom, director general of WHO.
The ACT-Accelerator was launched at the end of April, bringing together governments, health organizations, scientists, businesses, civil society and philanthropists.
They have outlined a plan that sees low and middle-income countries receiving 500 million diagnostic tests, 245 million courses of treatments, and two billion vaccine doses, before the end of next year.
This week, WHO warned that the global Covid-19 caseload was approaching 10 million. So far, more than 484,000 people have died from the disease.
"A safe and effective vaccine is the only way to prevent further spread and transmission of the new coronavirus," according to Dr Soumya Swaminathan, chief scientist at WHO.
Although it normally takes up to 10 years to develop and manufacture a vaccine, the partners are looking to significantly shorten that timeline.
"We're aiming for 12, maximum of 18 months. And that would be unprecedented," said Dr Swaminathan.
"The good news is we have over 200 candidates at some stage of clinical development; about 15 of them are actually now in human clinical trials."
WHO and partners will need $31.3 billion to achieve their goals. So far, $3.4 billion has been received.
"This is an investment worth making, more than any other we can think of," said Dr Ngozi Okonjo-Iweala, one of the two Special Envoys for the ACT-Accelerator.
"If we don't rally now, the human costs and economic pain will deepen. So, though these numbers sound big, they are not when we think of the alternatives."
